Sarepta Therapeutics Inc (NASDAQ:SRPT) was down 8% on Monday . The stock traded as low as $112.02 and last traded at $112.21. Approximately 1,197,138 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 1,277,756 shares. The stock had previously closed at $122.00.
Several equities research analysts have weighed in on SRPT shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $164.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, January 17th. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. Piper Jaffray Companies lifted their price objective on shares of Sarepta Therapeutics from $168.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, January 30th. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Finally, BTIG Research set a $190.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Tuesday, February 5th. One investment analyst has rated the stock with a hold rating, twenty-seven have given a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics currently has an average rating of “Buy” and an average target price of $193.18.
The firm has a market capitalization of $8.62 billion, a price-to-earnings ratio of -20.55 and a beta of 1.98. The company has a debt-to-equity ratio of 0.41, a quick ratio of 7.49 and a current ratio of 8.21.
A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in Sarepta Therapeutics by 6.9% during the fourth quarter. FMR LLC now owns 10,565,177 shares of the biotechnology company’s stock worth $1,152,977,000 after purchasing an additional 677,947 shares during the last quarter. Vanguard Group Inc boosted its holdings in Sarepta Therapeutics by 3.3% during the third quarter. Vanguard Group Inc now owns 5,384,899 shares of the biotechnology company’s stock worth $869,715,000 after purchasing an additional 170,999 shares during the last quarter. BlackRock Inc. boosted its holdings in Sarepta Therapeutics by 0.8% during the fourth quarter. BlackRock Inc. now owns 4,845,231 shares of the biotechnology company’s stock worth $528,758,000 after purchasing an additional 36,972 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Sarepta Therapeutics by 44.9% during the first quarter. Janus Henderson Group PLC now owns 2,666,043 shares of the biotechnology company’s stock worth $317,766,000 after purchasing an additional 826,449 shares during the last quarter. Finally, venBio Select Advisor LLC boosted its holdings in Sarepta Therapeutics by 35.1% during the fourth quarter. venBio Select Advisor LLC now owns 1,275,000 shares of the biotechnology company’s stock worth $139,141,000 after purchasing an additional 331,500 shares during the last quarter. Institutional investors and hedge funds own 93.48% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://dakotafinancialnews.com/2019/05/14/sarepta-therapeutics-srpt-trading-down-8.html.
Sarepta Therapeutics Company Profile (NASDAQ:SRPT)
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Recommended Story: What Are Cryptocurrencies?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.